Curaleaf Challenges Aurora's Rejection of $5.00 Per Share Bid

  • Curaleaf's enhanced offer represents an 86% premium to Aurora's unaffected 30-day volume-weighted average share price, and a 217% premium on an ex-cash basis.
  • Aurora's Board has denied Curaleaf diligence access while granting it to unnamed parties.
  • Aurora's Adjusted EBITDA declined 63% over the last two quarters, attributing it to industry-wide headwinds.
  • Curaleaf's implied transaction multiple for Aurora is 14.3x 2026 Adjusted EBITDA, higher than Curaleaf's multiple of 13.7x (IFRS).
  • Aurora sold shares under its ATM program for as low as $2.60 per share in July 2026.

Curaleaf's challenge to Aurora's rejection of its enhanced offer highlights a broader tension in the cannabis industry between strategic acquisitions and board-level resistance. The dispute underscores the importance of due diligence access and the potential for governance conflicts to derail value-maximizing deals. With Aurora's financial performance declining and Curaleaf offering a significant premium, the outcome will test the balance between shareholder interests and board discretion.

Governance Dynamics
Whether Aurora's Board can justify its rejection of Curaleaf's offer while granting diligence access to other parties.
Execution Risk
How Curaleaf's ability to substantiate its synergy estimates will impact the deal's progression.
Market Reactions
The pace at which Aurora's share price responds to the ongoing dispute and potential alternative bids.